Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Tofacitinib as Induction and Maintenance Therapy for Ulcerative ColitisThe New England journal of medicine, 2017-05, Vol.376 (18), p.1723-1736 [Peer Reviewed Journal]Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1606910 ;PMID: 28467869Full text available |
|
2 |
Material Type: Article
|
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trialThe lancet oncology, 2020-07, Vol.21 (7), p.935-946 [Peer Reviewed Journal]2020 Elsevier Ltd ;Copyright © 2020 Elsevier Ltd. All rights reserved. ;2020. Elsevier Ltd ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(20)30269-2 ;PMID: 32615108Full text available |
|
3 |
Material Type: Article
|
Clinical significance of Janus Kinase inhibitor selectivityRheumatology (Oxford, England), 2019-06, Vol.58 (6), p.953-962 [Peer Reviewed Journal]The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology. ;The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology. 2018 ;ISSN: 1462-0324 ;EISSN: 1462-0332 ;DOI: 10.1093/rheumatology/key339 ;PMID: 30508136Full text available |
|
4 |
Material Type: Article
|
Clinicogenomic Analysis of FGFR2 -Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to PemigatinibCancer discovery, 2021-02, Vol.11 (2), p.326-3392020 American Association for Cancer Research. ;ISSN: 2159-8274 ;EISSN: 2159-8290 ;DOI: 10.1158/2159-8290.cd-20-0766 ;PMID: 33218975Full text available |
|
5 |
Material Type: Article
|
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell CarcinomaThe New England journal of medicine, 2018-08, Vol.379 (5), p.417-427 [Peer Reviewed Journal]Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1803675 ;PMID: 29860937Full text available |
|
6 |
Material Type: Article
|
Ubrogepant for the Treatment of MigraineThe New England journal of medicine, 2019-12, Vol.381 (23), p.2230-2241 [Peer Reviewed Journal]Copyright © 2019 Massachusetts Medical Society. All rights reserved. ;Copyright © 2019 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1813049 ;PMID: 31800988Full text available |
|
7 |
Material Type: Article
|
Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositisRheumatology (Oxford, England), 2018-12, Vol.57 (12), p.2114-2119 [Peer Reviewed Journal]The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2018 ;ISSN: 1462-0324 ;EISSN: 1462-0332 ;DOI: 10.1093/rheumatology/key188 ;PMID: 30060040Full text available |
|
8 |
Material Type: Article
|
Acid‐inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects ‐ a randomised open‐label cross‐over studyAlimentary pharmacology & therapeutics, 2015-09, Vol.42 (6), p.719-730 [Peer Reviewed Journal]2015 The Authors. published by John Wiley & Sons Ltd. ;2015 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd. ;ISSN: 0269-2813 ;EISSN: 1365-2036 ;DOI: 10.1111/apt.13325 ;PMID: 26193978Full text available |
|
9 |
Material Type: Article
|
Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque PsoriasisJournal of investigative dermatology, 2014-12, Vol.134 (12), p.2988-2990 [Peer Reviewed Journal]2014 The Society for Investigative Dermatology, Inc ;Copyright Nature Publishing Group Dec 2014 ;ISSN: 0022-202X ;EISSN: 1523-1747 ;DOI: 10.1038/jid.2014.260 ;PMID: 24940651Full text available |
|
10 |
Material Type: Article
|
Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical TrialClinical journal of the American Society of Nephrology, 2020-12, Vol.15 (12), p.1715-1727 [Peer Reviewed Journal]Copyright © 2020 by the American Society of Nephrology. ;Copyright © 2020 by the American Society of Nephrology 2020 ;ISSN: 1555-9041 ;EISSN: 1555-905X ;DOI: 10.2215/CJN.06870520 ;PMID: 33239409Full text available |
|
11 |
Material Type: Article
|
Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in JapanGut, 2020-06, Vol.69 (6), p.1019-1026 [Peer Reviewed Journal]Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2020 Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2020 ;ISSN: 0017-5749 ;EISSN: 1468-3288 ;DOI: 10.1136/gutjnl-2019-319954 ;PMID: 31915235Full text available |
|
12 |
Material Type: Article
|
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trialThe lancet oncology, 2020-10, Vol.21 (10), p.1296-1308 [Peer Reviewed Journal]2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2020. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2020 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(20)30444-7 ;PMID: 32919527Full text available |
|
13 |
Material Type: Article
|
Targeting renal cell carcinoma with a HIF-2 antagonistNature (London), 2016-11, Vol.539 (7627), p.112-117 [Peer Reviewed Journal]COPYRIGHT 2016 Nature Publishing Group ;COPYRIGHT 2016 Nature Publishing Group ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/nature19796 ;PMID: 27595394Full text available |
|
14 |
Material Type: Article
|
The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritisClinical and experimental rheumatology, 2016-03, Vol.34 (2), p.318-328 [Peer Reviewed Journal]ISSN: 0392-856X ;EISSN: 1593-098X ;PMID: 26966791Full text available |
|
15 |
Material Type: Article
|
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF InhibitorsThe New England journal of medicine, 2017-10, Vol.377 (16), p.1525-1536 [Peer Reviewed Journal]Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1615977 ;PMID: 29045207Full text available |
|
16 |
Material Type: Article
|
Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid ArthritisArthritis & rheumatology (Hoboken, N.J.), 2014-10, Vol.66 (10), p.2675-2684 [Peer Reviewed Journal]2014 The Authors. Arthritis & Rheumatology is published by Wiley Periodicals, Inc. on behalf of the American College of Rheumatology. ;Copyright © 2014 by the American College of Rheumatology ;2014 The Authors. Arthritis & Rheumatology is published by Wiley Periodicals, Inc. on behalf of the American College of Rheumatology. 2014 ;ISSN: 2326-5191 ;EISSN: 2326-5205 ;DOI: 10.1002/art.38745 ;PMID: 24943354Full text available |
|
17 |
Material Type: Article
|
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trialThe Lancet (British edition), 2017-07, Vol.390 (10093), p.457-468 [Peer Reviewed Journal]Elsevier Ltd ;2017 Elsevier Ltd ;Copyright © 2017 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jul 29, 2017 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(17)31618-5 ;PMID: 28629665Full text available |
|
18 |
Material Type: Article
|
The emerging safety profile of JAK inhibitors in rheumatic diseaseNature reviews. Rheumatology, 2017-04, Vol.13 (4), p.234-243 [Peer Reviewed Journal]COPYRIGHT 2017 Nature Publishing Group ;COPYRIGHT 2017 Nature Publishing Group ;Copyright Nature Publishing Group Apr 2017 ;ISSN: 1759-4790 ;EISSN: 1759-4804 ;DOI: 10.1038/nrrheum.2017.23 ;PMID: 28250461Full text available |
|
19 |
Material Type: Article
|
AKT Inhibition in Solid Tumors With AKT1 MutationsJournal of clinical oncology, 2017-07, Vol.35 (20), p.2251-2259 [Peer Reviewed Journal]2017 by American Society of Clinical Oncology 2017 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2017.73.0143 ;PMID: 28489509Full text available |
|
20 |
Material Type: Article
|
Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion StudyCancer discovery, 2022-02, Vol.12 (2), p.402-4152021 The Authors; Published by the American Association for Cancer Research. ;Attribution - NonCommercial - NoDerivatives ;2021 The Authors; Published by the American Association for Cancer Research 2021 American Association for Cancer Research ;ISSN: 2159-8274 ;EISSN: 2159-8290 ;DOI: 10.1158/2159-8290.CD-21-0697 ;PMID: 34551969Full text available |